Search Results for: DNA VACCINES MARKET DNA Vaccines
Articles
Paragon Bioservices to be Acquired for $1.2 Billion April 15, 2019
Catalent, Inc. and Paragon Bioservices, Inc. and Catalent Inc. recently announced they have entered into a definitive agreement under which Catalent will acquire Paragon for $1.2 billion.
CLINICAL TRIALS - Maximizing Immuno-Oncology Clinical Trial Success June 4, 2018
Luke S. Gill, MSc, MBA, believes understanding and overcoming various challenges in the development of immunotherapeutic agents will be critical to clinical trial success and, ultimately, market approval.
Inovio Closes License & Collaboration Agreement With ApolloBio March 23, 2018
Inovio Pharmaceuticals, Inc. recently announced it has closed an agreement providing ApolloBio Corp. with the exclusive right to develop, manufacture,...Inovio Enters License & Collaboration Agreement With ApolloBio January 8, 2018
Inovio Pharmaceuticals, Inc. recently announced it entered an amended agreement providing ApolloBio Corporation with the exclusive right to develop and...Cobra Biologics Embarks on Gene Therapy Manufacturing Operations Expansion April 24, 2017
Cobra Biologics, an international CDMO of biologics and pharmaceuticals, recently announced it is to expand operations at its sites in...SPECIAL FEATURE - Platform Technologies: Not Just for Big Pharma October 3, 2016
Contributor Cindy H. Dubin recently spoke with several companies that are debunking the theory that access to the latest technological platforms to aid efficient drug discovery and development is limited to Big Pharma, which can more easily justify the costs of creating and operating innovative platforms.
Inovio Partners With National Cancer Institute & Mayo Clinic to Initiate Hepatitis C Immunotherapy Clinical Trial May 2, 2016
Inovio Pharmaceuticals, Inc. recently announced its immunotherapy for hepatitis C (INO-8000) will be evaluated in a Phase I trial in...EXECUTIVE INTERVIEW - ALTHEA: Giving Biopharmaceutical Companies the Power To Make October 5, 2015
David Enloe, Althea’s President and CEO, discusses his company’s business strategy, why companies choose Althea, trends in the CMO industry, and how the company is growing since the acquisition of Ajinomoto.
Immune Response BioPharma to Develop In-House Sales Force for Blockbuster Vaccine August 12, 2014
New Jersey-based Immune Response BioPharma, Inc. recently announced its plans to create an in-house sales force for Remune, its HIV...INTRADERMAL DELIVERY - Advances in Intradermal Drug Delivery October 16, 2013
Zach Marks, MS, RPh, believes efficiency of vaccine use will be critical as the world population continues to grow and vaccine prices continue to rise, and ID administration can help reduce dose cost while potentially improving immunogenicity in traditional and hard-to-treat populations.
THERAPEUTIC FOCUS - New Therapeutics for Aggressive Brain Cancers October 3, 2013
Jeffrey Bacha, MBA, says glioblastoma is one of the most common and fatal brain cancers, and new therapies to treat this disease are urgently needed. New approaches, such as vaccines and immunotherapies, have promising results, and to be most effective, will need to be used in combination with a chemotherapeutic.
Roche & Inovio Enter $422.5-Million Licensing Deal September 18, 2013
Roche and Inovio Pharmaceuticals, Inc. recently announced they have entered into an exclusive worldwide license agreement to research, develop and...FORMULATION DEVELOPMENT - Trends & Opportunities in Particle Design Technologies - Life Sciences & Biopharma in the Spotlight April 30, 2013
Frost & Sullivan Analyst, Cecilia Van Cauwenberghe, MS, examines the observed trends in particle design and engineering technologies, as well as the main factors and opportunities driving the principal technological advances in the biopharmaceutical industry.
DELIVERY DEVICES - The New Industry Paradigm for Prefilled Success March 12, 2013
Alan Shortall indicates that following a period of relative industry stability defined by peripheral innovation, a converging series of external and internal forces are set to reshape the prefilled syringe industry so that it will better serve the emerging needs of pharmaceutical companies, patients, and other stakeholders across the continuum of care.
3/6/2013 February 28, 2013
Capsugel Announces Major Acquisition Capsugel recently announced it has acquired Encap Drug Delivery. Based in Scotland, Encap's focus on liquid and...1/23/2012 January 21, 2013
Amgen Invests $200 Million in Monoclonal Antibodies Amgen recently announced plans to build a new manufacturing facility in the Tuas...7/18/2012 July 12, 2012
Prokarium Acquires Key Oral Vaccine Technology Prokarium Ltd recently announced it completed a key technology acquisition from Emergent BioSolutions Inc....Prokarium Acquires Key Oral Vaccine Technology July 12, 2012
Prokarium Ltd recently announced it completed a key technology acquisition from Emergent BioSolutions Inc. The technology includes Emergent's live Salmonella-based...5/16/2012 May 14, 2012
Mucosis Announces Positive Data for Mimopath Platform Mucosis B.V. recently announced Phase I clinical data providing proof-of-concept that Mimopath-based mucosal...4/3/2012 March 29, 2012
Aptar Pharma's Device Delivers INSYS Therapeutics' Drug Aptar Pharma recently announced INSYS Therapeutics' SUBSYS, which uses an Aptar Pharma Sublingual...
